Recombinant kinase inhibition profile
Biochemical assay · Recombinant kinase domains and peptide substrates [1]
AP24534 inhibited ABL and ABL T315I and several other tyrosine kinases; activity was weaker against the selected insulin-signaling and serine/threonine kinase comparators.
| Endpoint | Reported result | Reference |
|---|---|---|
| Native ABL catalytic inhibition | IC50 0.37 nM | [1] |
| ABL T315I catalytic inhibition | IC50 2.0 nM | [1] |
| c-SRC catalytic inhibition | IC50 5.4 nM | [1] |
| LYN catalytic inhibition | IC50 0.24 nM | [1] |
| c-KIT catalytic inhibition | IC50 12.5 nM | [1] |
| VEGFR2 catalytic inhibition | IC50 1.5 nM | [1] |
| FGFR1 catalytic inhibition | IC50 2.2 nM | [1] |
| PDGFRα catalytic inhibition | IC50 1.1 nM | [1] |
| Insulin receptor catalytic inhibition | IC50 >1000 nM | [1] |
| IGF-1R catalytic inhibition | IC50 >1000 nM | [1] |
| Aurora A catalytic inhibition | IC50 >1000 nM | [1] |
| CDK2/Cyclin E catalytic inhibition | IC50 >1000 nM | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Ten inhibitor concentrations; exact series not stated in the main kinase-profile methods.
- Method
- Cell-free kinase inhibition profiling
- Co-treatment
- Single-agent ponatinib/AP24534; comparator/control groups are separate.
- Reported limits
- Incubation duration, vehicle, replicate number and uncertainty estimates are not specified for Table 1 in the read main text.
Methods and source locations
Compound reported in the paper: AP24534 (ponatinib); Compound label in the paper: AP24534
Literature pharmacology of the ponatinib active moiety. Animal doses are those reported by the authors; no free-base/hydrochloride mass conversion or formulation equivalence is established.
Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534
Native ABL catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534
ABL T315I catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534
c-SRC catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534
LYN catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534
c-KIT catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534
VEGFR2 catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534
FGFR1 catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534
PDGFRα catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534
Insulin receptor catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534
IGF-1R catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534
Aurora A catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534
CDK2/Cyclin E catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534